肿瘤学家对积极治疗的癌症患者接种疫苗的认识和经验

Nervana Hussien, M. EzzEldin, A. Abdelaziz, Haitham M Ahmed, M. El kassas, I. Elzayat, W. Elkhatib, Soha Ahmed
{"title":"肿瘤学家对积极治疗的癌症患者接种疫苗的认识和经验","authors":"Nervana Hussien, M. EzzEldin, A. Abdelaziz, Haitham M Ahmed, M. El kassas, I. Elzayat, W. Elkhatib, Soha Ahmed","doi":"10.21608/jcbr.2022.120116.1248","DOIUrl":null,"url":null,"abstract":"Background : The COVID-19 epidemic has wreaked havoc on individuals of all ages throughout the world. I In unprecedented time frame, its vaccination has been produced and made available to the general population. However, due to varying levels of its acceptance, vaccination did not gain widespread adoption. Aim: We aimed to measure the perception and experience of oncologists towards COVID-19 vaccination in cancer patients on active therapy. Methods: A cross-sectional survey with a self-administered questionnaire was circulated among oncology specialists in Egypt between September – and December 2021. Results: A total of 83 respondents participated of which 59% had more than 10 years of experience in the oncology field. The majority of the respondents 75 (90.4%) recommended giving the vaccine once available in case of hormonal treatment meanwhile the lowest percentage 32 (38.5%) was for anti CD20 monoclonal antibody, either as a single agent or combined with chemotherapy. Choices of 49 (59%), 46 (55%), and 43 (51.8%) to vaccinate patients on active treatment with cytotoxic chemotherapy, MoAb (except anti CD20), and immunotherapy respectively were reported. The inactivated COVID-19 virus vaccine was recommended by 39 (47%), followed by Vector vaccines in 20 (24.1%), 8 (9.6%) for the messenger RNA (mRNA) vaccines, while 16(19.3%) of them were undecided. Thirty-nine (47%) of the participants reported that patients on active treatment developed side effects from vaccination. The most conveyed side effects were fatigue in 34 (87%), fever or a local reaction each in 28 (71.8%), headache and myalgia equally in 19 (48.7%), and chills in 11 (28.2%), and myalgia in10 (25.6 %). Conclusion: Strategies to address the practicality of dealing with vaccination in cancer patients are needed. Emphasis on the installation of the latest data in caring for this population and increased awareness of the services provided is crucial. Surveys are a useful tool reflecting real-world practice.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"26 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Perception and Experience of Oncologists regarding Vaccination of Cancer Patients on Active Treatment\",\"authors\":\"Nervana Hussien, M. EzzEldin, A. Abdelaziz, Haitham M Ahmed, M. El kassas, I. Elzayat, W. Elkhatib, Soha Ahmed\",\"doi\":\"10.21608/jcbr.2022.120116.1248\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background : The COVID-19 epidemic has wreaked havoc on individuals of all ages throughout the world. I In unprecedented time frame, its vaccination has been produced and made available to the general population. However, due to varying levels of its acceptance, vaccination did not gain widespread adoption. Aim: We aimed to measure the perception and experience of oncologists towards COVID-19 vaccination in cancer patients on active therapy. Methods: A cross-sectional survey with a self-administered questionnaire was circulated among oncology specialists in Egypt between September – and December 2021. Results: A total of 83 respondents participated of which 59% had more than 10 years of experience in the oncology field. The majority of the respondents 75 (90.4%) recommended giving the vaccine once available in case of hormonal treatment meanwhile the lowest percentage 32 (38.5%) was for anti CD20 monoclonal antibody, either as a single agent or combined with chemotherapy. Choices of 49 (59%), 46 (55%), and 43 (51.8%) to vaccinate patients on active treatment with cytotoxic chemotherapy, MoAb (except anti CD20), and immunotherapy respectively were reported. The inactivated COVID-19 virus vaccine was recommended by 39 (47%), followed by Vector vaccines in 20 (24.1%), 8 (9.6%) for the messenger RNA (mRNA) vaccines, while 16(19.3%) of them were undecided. Thirty-nine (47%) of the participants reported that patients on active treatment developed side effects from vaccination. The most conveyed side effects were fatigue in 34 (87%), fever or a local reaction each in 28 (71.8%), headache and myalgia equally in 19 (48.7%), and chills in 11 (28.2%), and myalgia in10 (25.6 %). Conclusion: Strategies to address the practicality of dealing with vaccination in cancer patients are needed. Emphasis on the installation of the latest data in caring for this population and increased awareness of the services provided is crucial. Surveys are a useful tool reflecting real-world practice.\",\"PeriodicalId\":428417,\"journal\":{\"name\":\"International Journal of Cancer and Biomedical Research\",\"volume\":\"26 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Cancer and Biomedical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/jcbr.2022.120116.1248\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/jcbr.2022.120116.1248","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:2019冠状病毒病(COVID-19)疫情对全世界各个年龄段的人造成了严重破坏。在前所未有的时间框架内,已生产并向普通民众提供了疫苗接种。然而,由于接受程度不同,疫苗接种并没有得到广泛采用。目的:我们旨在衡量肿瘤学家对积极治疗的癌症患者接种COVID-19疫苗的看法和经验。方法:在2021年9月至12月期间,在埃及的肿瘤专家中进行了一项带有自我管理问卷的横断面调查。结果:共有83名受访者参与,其中59%的人在肿瘤领域有10年以上的经验。大多数应答者75(90.4%)建议在激素治疗的情况下立即接种疫苗,而最低百分比32(38.5%)是抗CD20单克隆抗体,作为单一药物或与化疗联合使用。分别有49例(59%)、46例(55%)和43例(51.8%)患者在细胞毒性化疗、MoAb(抗CD20除外)和免疫治疗的积极治疗中选择接种疫苗。39人(47%)推荐新冠病毒灭活疫苗,20人(24.1%)推荐载体疫苗,8人(9.6%)推荐信使RNA (mRNA)疫苗,16人(19.3%)不确定。39名(47%)参与者报告说,接受积极治疗的患者出现了接种疫苗的副作用。最常见的副作用是疲劳34例(87%),发热或局部反应28例(71.8%),头痛和肌痛同时发生19例(48.7%),寒战11例(28.2%),肌痛10例(25.6%)。结论:需要采取措施解决癌症患者接种疫苗的实用性问题。在照顾这一人口和提高对所提供服务的认识方面,强调采用最新数据是至关重要的。调查是反映现实世界实践的有用工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Perception and Experience of Oncologists regarding Vaccination of Cancer Patients on Active Treatment
Background : The COVID-19 epidemic has wreaked havoc on individuals of all ages throughout the world. I In unprecedented time frame, its vaccination has been produced and made available to the general population. However, due to varying levels of its acceptance, vaccination did not gain widespread adoption. Aim: We aimed to measure the perception and experience of oncologists towards COVID-19 vaccination in cancer patients on active therapy. Methods: A cross-sectional survey with a self-administered questionnaire was circulated among oncology specialists in Egypt between September – and December 2021. Results: A total of 83 respondents participated of which 59% had more than 10 years of experience in the oncology field. The majority of the respondents 75 (90.4%) recommended giving the vaccine once available in case of hormonal treatment meanwhile the lowest percentage 32 (38.5%) was for anti CD20 monoclonal antibody, either as a single agent or combined with chemotherapy. Choices of 49 (59%), 46 (55%), and 43 (51.8%) to vaccinate patients on active treatment with cytotoxic chemotherapy, MoAb (except anti CD20), and immunotherapy respectively were reported. The inactivated COVID-19 virus vaccine was recommended by 39 (47%), followed by Vector vaccines in 20 (24.1%), 8 (9.6%) for the messenger RNA (mRNA) vaccines, while 16(19.3%) of them were undecided. Thirty-nine (47%) of the participants reported that patients on active treatment developed side effects from vaccination. The most conveyed side effects were fatigue in 34 (87%), fever or a local reaction each in 28 (71.8%), headache and myalgia equally in 19 (48.7%), and chills in 11 (28.2%), and myalgia in10 (25.6 %). Conclusion: Strategies to address the practicality of dealing with vaccination in cancer patients are needed. Emphasis on the installation of the latest data in caring for this population and increased awareness of the services provided is crucial. Surveys are a useful tool reflecting real-world practice.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信